for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Diffusion Pharmaceuticals Inc

DFFN.OQ

Latest Trade

1.04USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.22

 - 

2.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.04
Open
--
Volume
--
3M AVG Volume
116.86
Today's High
--
Today's Low
--
52 Week High
2.39
52 Week Low
0.22
Shares Out (MIL)
64.00
Market Cap (MIL)
69.76
Forward P/E
-4.45
Dividend (Yield %)
--

Latest Developments

More

Diffusion Pharmaceuticals Reports Qtrly Loss Per Share $0.10

Diffusion - Entire Phase 1A/1B Trial Will Enroll About 224 Patients And Is Expected To Last Approximately 12 Months

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Diffusion Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Industry

Biotechnology & Drugs

Contact Info

2020 Avon Ct Ste 4

CHARLOTTESVILLE, VA

22902-8734

United States

+1.434.2200718

https://diffusionpharma.com/

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-29.682

2018

-8.374

2019

-1.795

2020(E)

-0.275
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-46.99
Return on Equity (TTM)
-44.57

Latest News

Latest News

BRIEF-Diffusion Pharmaceuticals Files IND For International Phase 1B/2B Covid-19 Clinical Program With TSC

* DIFFUSION PHARMACEUTICALS FILES IND FOR INTERNATIONAL PHASE 1B/2B COVID-19 CLINICAL PROGRAM WITH TSC

BRIEF-Diffusion - Entire Phase 1A/1B Trial Will Enroll About 224 Patients And Is Expected To Last Approximately 12 Months

* DIFFUSION PHARMACEUTICALS FILES CLINICAL TRIAL APPLICATION FOR EUROPEAN PHASE 1A/1B STUDY OF TSC IN COVID-19 PATIENTS

BRIEF-Diffusion Pharma Files Prospectus Related To Resale Of Shares By Selling Stockholders

* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, BY SELLING STOCKHOLDERS OF UP TO 5.8 MILLION SHARES OF COMMON STOCK Source text: (https://bit.ly/36Fzfcf) Further company coverage:

BRIEF-Diffusion Pharma Reports $12 Million Registered Direct Offering

* DIFFUSION PHARMACEUTICALS INC. ANNOUNCES $12 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Diffusion Pharmaceuticals Announces Pre-Ind Submission To The FDA Of Design For Tsc Trials To Treat Acute Respiratory Distress Syndrome In Covid-19

* DIFFUSION PHARMACEUTICALS ANNOUNCES PRE-IND SUBMISSION TO THE FDA OF DESIGN FOR TSC TRIALS TO TREAT ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19

BRIEF-Diffusion Evaluating TSC Against Acute Respiratory Distress Syndrome In Covid-19 Patients

* DIFFUSION PHARMACEUTICALS EVALUATING TSC AGAINST ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN COVID-19 PATIENTS

BRIEF-Diffusion Pharmaceuticals - Expect Delays In Enrollment In Ambulance-Based Phast-Tsc Phase 2 Clinical Trial In Acute Stroke Due To Coronavirus

* DIFFUSION PHARMACEUTICALS ANTICIPATES ENROLLMENT IN ITS AMBULANCE-BASED STROKE TRIAL WILL BE SLOWED DUE TO THE IMPACT OF THE CORONAVIRUS

BRIEF-Diffusion Pharmaceuticals Reports 2019 Financial Results And Provides Business Update

* DIFFUSION PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Diffusion Pharma Gets European Patent Related Compositions Of TSC

* DIFFUSION PHARMACEUTICALS RECEIVES EUROPEAN PATENT RELATED COMPOSITIONS OF TSC Source text for Eikon: Further company coverage:

BRIEF-Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock

* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2nGHE9Q) Further company coverage:

BRIEF-Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering

* DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING

BRIEF-Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme

* DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME

BRIEF-Diffusion Pharma Files For Stock Offering For Up To About $15 Mln

* DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2BbtOBi) Further company coverage:

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up